11th Sep 2015 11:23
LONDON (Alliance News) - Isis Pharmaceuticals, Inc Friday said its collaboration with AstraZeneca to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
AstraZeneca will pay Isis a USD65 million up-front payment. Isis is also eligible to receive development and regulatory milestones for each program that AstraZeneca advances to clinical development.
Isis is also eligible to earn tiered double-digit royalties on annual net sales for each program.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca